Globus Medical (GMED) CEO Keith Pfeil awarded 100,000 stock options

Rhea-AI Filing Summary

Globus Medical Inc. reported a new stock option grant to its President and CEO, Keith W. Pfeil. On January 21, 2026, Pfeil received stock options giving him the right to buy 100,000 shares of Class A common stock at an exercise price of $94.15 per share. The options were granted at no cost to him as compensation and expire on January 21, 2036.

The award vests over four years, with one-quarter of the options vesting on January 1, 2027 and the remaining options vesting in equal monthly installments (1/48 of the total) each month thereafter. All 100,000 options are reported as held directly by Pfeil following this grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pfeil Keith W

Role President, CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy Class A Common Stock)	100,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy Class A Common Stock) — 100,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pfeil Keith W

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON PA 19403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)	$94.15	01/21/2026		A		100,000		(1)	01/21/2036	Class A Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. These options were granted on January 21, 2026, and vest over a four-year period with 1/4 of the options vesting on January 1, 2027, and then 1/48 of the options vesting each month thereafter.

	/s/ Kelly G. Huller, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Globus Medical (GMED) disclose in this Form 4?

Globus Medical disclosed that President and CEO Keith W. Pfeil received a grant of stock options on January 21, 2026, covering 100,000 shares of Class A common stock.

What are the key terms of Keith W. Pfeil’s new stock options at Globus Medical (GMED)?

The options allow Pfeil to buy 100,000 shares of Class A common stock at an exercise price of $94.15 per share, with an expiration date of January 21, 2036.

How do Keith W. Pfeil’s Globus Medical (GMED) options vest?

The options vest over four years: 1/4 vests on January 1, 2027, and the remaining 3/4 vest in equal monthly installments of 1/48 of the total options each month thereafter.

How many derivative securities does Keith W. Pfeil hold after this GMED transaction?

After the reported grant, Keith W. Pfeil beneficially owns 100,000 stock options related to Globus Medical Class A common stock, held directly.

Is this Globus Medical (GMED) Form 4 an insider purchase or sale of common stock?

This Form 4 reports a grant of stock options, not a market purchase or sale of common stock. It is an award giving the CEO the right to buy shares in the future at a fixed exercise price.

Who is the insider involved in this Globus Medical (GMED) Form 4 filing?

The reporting person is Keith W. Pfeil, who is both a Director and the President, CEO of Globus Medical Inc.